ALFA Filings
Every announcement, straight from the exchange
Every Solara Active Pharma Sciences earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements
Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.
Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.
Solara achieved record EBITDA/PAT despite significant geopolitical headwinds in West Asia impacting raw material costs.
Solara delivered its highest Q4 revenue in 8 quarters at INR 392cr, driven by a strong base business with 54% gross margins, despite persistent headwinds and negative EBITDA in the Ibuprofen segment.
Solara's base business shows strong momentum, hitting eight-quarter highs in revenue and EBITDA, yet the Ibuprofen segment remains a significant drag, forcing a strategic review and potential divestment of the vertical.